<p>Editors ChoiceMain Category: Alzheimers / Dementia
Also Included In: Clinical Trials / Drug Trials
Article Date: 13 Apr 2012 10:00 PDT</p>
<p> email to a crony printer accessible opinions </p>
<p>! rate article</p>
<p>Patient / Public:
5 (2 votes)
Healthcare Prof:</p>
<p>
According to GE Healthcare, a rough formula of dual Phase 3 studies of their investigational PET amyloid-imaging agent, [18F]flutemetamol, a GE Healthcare PET imaging representative grown to detect beta amyloid, both met their primary endpoints. Full formula of both studies will be presented in a nearby future.</p>
<p>One of a studies concerned terminally ill patients, who concluded to bear mind autopsy, displaying clever organisation between flutemetamol PET images and beta amyloid mind pathology related to Alzheimers illness (AD), while a other investigate was achieved in young, healthy volunteers subsequent a age of 40 years, and a...
0 comments
Post a Comment